



Europäisches Patentamt  
European Patent Office  
Office européen des brevets

⑪ Publication number:

0 347 066  
A1

⑫

## EUROPEAN PATENT APPLICATION

㉑ Application number: 89305532.7

㉑ Int. Cl. 4 C07D 307/87, A61K 31/34,  
//C07B57/00, C07C121/80,  
C07C143/68

㉒ Date of filing: 01.06.89

㉓ Priority: 14.06.88 GB 8814057

㉑ Applicant: H. LUNDBECK A/S  
Ottillavej 7-9  
DK-2500 Kobenhavn-Valby(DK)

㉔ Date of publication of application:  
20.12.89 Bulletin 89/51

㉒ Inventor: Boegesoe, Klaus Peter  
15, Moelleaaparken  
DK-2800 Lyngby(DK)  
Inventor: Perregaard, Jens  
22, Thyrasvej  
DK-3630 Jaegerspris(DK)

㉔ Designated Contracting States:  
AT BE CH DE ES FR GB GR IT LI LU NL SE

㉔ Representative: Wilkinson, Stephen John et al  
c/o Stevens, Hewlett & Perkins 5 Quality  
Court Chancery Lane  
London WC2A 1HZ(GB)

㉔ New enantiomers and their isolation.

㉔ The novel (+)-enantiomer of 1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile as well as acid addition salts thereof are described as valuable antidepressants, geriatrics or in the treatment of obesity and alcoholism.


Novel intermediates and a method for the preparation of the (+)-enantiomer as well as the racemic mixture are described.

EP 0 347 066 A1

## NEW ENANTIOMERS AND THEIR ISOLATION

The present invention relates to the two novel enantiomers of the antidepressant drug 1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile (citalopram) of the following formula I:

5



I

10

15

and to the use of these enantiomers as antidepressant compounds as well as the possible use as geriatrics or in the cure of obesity or alcoholism.

This invention also includes pharmaceutically acceptable salts of the enantiomers of compound I formed with non-toxic organic or inorganic acids. Such salts are easily prepared by methods known to the art. The base is reacted with either the calculated amount of organic or inorganic acid in an aqueous miscible solvent, such as acetone or ethanol, with isolation of the salt by concentration and cooling or an excess of the acid in aqueous immiscible solvent, such as ethyl ether, ethyl acetate or dichloromethane, with the desired salt separating directly. Exemplary of such organic salt are those with maleic, fumaric, benzoic, ascorbic, pamoic, succinic, oxalic, salicylic, methanesulfonic, ethanesulfonic, acetic, propionic, tartaric, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-amino-benzoic, glutamic, benzene sulfonic and theophylline acetic acid, as well as the 8-halotheophyllines, for example 8-bromotheophylline.


Exemplary of such inorganic salts are those with hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acids. Of course, these salts may also be prepared by the conventional method of double decomposition of appropriate salts, which is well-known to the art.

Furthermore it was found that non-hygroscopic acid addition salts might be obtained by conventional freeze drying techniques from water solutions of appropriate salts of the above mentioned kinds.

The invention is also concerned with a method to resolve the racemate of I into the individual isomers. Citalopram, which has been disclosed in eg. US Patent No. 4,136,193, has proven to be an efficient antidepressant compound in man (Ref.: A. Gravem et al., Acta Psychiat. Scand., No. 75, p. 478-486 (1987)). All work in the development of this compound has been made with the racemate. Citalopram has been shown pharmacologically to be a very selective inhibitor of 5-HT reuptake. Previous attempts to crystallize diastereomeric salts of citalopram enantiomers have failed.

Surprisingly, it has now proven possible to resolve the intermediate 4-(4-dimethylamino)-1-(4'-fluorophenyl)-1-(hydroxybutyl)-3-(hydroxymethyl)benzonitrile, II, into its enantiomers and finally in a stereoselective way to convert these enantiomers to the corresponding citalopram enantiomers. Likewise, monoesters of II formed by optically active carboxylic acids could be separated into the corresponding diastereomers and subsequently converted directly into citalopram enantiomers in a stereoselective ring-closure reaction. The intermediate diol, II, has been disclosed in eg. US Patent No. 4,650,884 as a racemic mixture.

50



The enantiomers of the intermediate of formula II as well as monoesters fall likewise within the scope of the present invention.

15 Furthermore, it was shown to our surprise that almost the entire 5-HT uptake inhibition resided in the (+)-citalopram enantiomer.

The present invention also includes a new method of synthesizing I from the diol compound II by esterification of the primary alcohol group into a labile ester, which in the presence of a base undergoes spontaneous ringclosure to citalopram or, if enantiomerically pure II is esterified, the corresponding 20 citalopram enantiomer is produced with fully conservation of stereoconfiguration.

20 According to the invention, II is reacted with:

25 a) an enantiomerically pure acid derivative as an acid chloride, anhydride or labile ester as eg. exemplified in reaction scheme I by (+)- or (-)- $\alpha$ -methoxy- $\alpha$ -trifluoromethylphenylacetyl chloride. The reaction is preferably performed in an inert organic solvent as eg. toluene, dichloromethane or tetrahydrofuran. A base (triethylamine, N,N-dimethylaniline, pyridin or the like) is added to neutralize 30 liberated HCl. The diastereoisomers are subsequently separated by HPLC or fractional crystallization. The thus purified diastereoisomers are finally separately treated with strong base (eg. alkoxide) in an inert organic solvent as eg. toluene, tetrahydrofuran, or dimethoxyethane yielding the pure citalopram enantiomers respectively. The ringclosure reaction is preferably performed at relatively low temperatures (-20°C to room temperature).

35


40

45

50


55

5

REACTION SCHEME I

b) the enantiomers of an optically active acid successively affording the pure diastereomeric salts. Optically antipodes of tartaric acid, di-benzoyltartaric acid, di-(p-toloyl)tartaric acid, bisnaphthylphosphoric acid, 10-camphorsulphonic acid and the like are conveniently used.

50 c) Stereoselective ringclosure of the pure enantiomers of II prepared as in b) is performed via a labile ester as eg. methansulfonyl, p-toluenesulfonyl, 10-camphorsulfonyl, trifluoroacetyl or trifluoromethansulfonyl with simultaneous addition of a base (triethylamine, dimethylaniline or pyridin) in an inert organic solvent at 0°C. The ringclosure reaction is exemplified in reaction scheme II:

REACTION SCHEME IIEXAMPLE 1Resolution by method a)

To 11 g of (+)-1-methoxy- $\alpha$ -trifluoromethylacetic acid dissolved in 25 ml of chloroform were added 50 ml of thionylchloride and a few drops of dimethylformamide. The reaction mixture was refluxed for 2 hours. Excess of thionylchloride was evaporated with toluene leaving the (+)- $\alpha$ -methoxy- $\alpha$ -trifluoromethylacetyl chloride as a liquid. This liquid diluted with 50 ml of dichloromethane was added dropwise to an ice cooled solution of 17 gr of 4-(4-dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl)-3-(hydroxymethyl)-benzonitrile, II, and 8 ml of triethylamine in 150 ml of dichloromethane. The reaction mixture was further stirred for another hour at room temperature, subsequently washed with brine, dried (MgSO<sub>4</sub>) and the solvent evaporated below 30°C in vacuo affording 29 gr of the ester as a diastereomeric mixture. By repeated

HPLC purification (eluted with ethyl acetate / tetrahydrofuran 9:1 containing 4% of triethylamine) and by collecting only the 5-10% initial substance in the main peak, 1.1 gr of enantiomerically pure compound was isolated.

The substance thus isolated was dissolved in dry toluene (50 ml) and added to a suspension of 0.3 gr of potassium t-butoxide in 20 ml of toluene at 0°C. The toluene solution was washed with water, dried ( $\text{MgSO}_4$ ) and the solvent evaporated yielding 0.6 gr of (+)-1-(dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile as an oil.  $[\alpha]_D = +11.81^\circ$  (c = 1,  $\text{CH}_3\text{OH}$ ) (determined with a substance containing 10% w/w of methanol). The optical purity was determined by  $^1\text{H}$  NMR spectroscopy ( $\text{CDCl}_3$  as solvent) (Bruker AC-250 MHz instrument) by addition of a 10:1 w/w surplus of the chiral reagent (-)-2,2,2-trifluoro-1-(9-anthryl)ethanol. Optical purity: 99.6%.

In a totally analogous way the (-)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile was synthesized.  $[\alpha]_D = -12.34^\circ$  (c = 1,  $\text{CH}_3\text{OH}$ ) (determined with a substance containing 10% w/w of methanol). Optical purity: 99.9%.

15

### EXAMPLE 2

#### Resolution by methods b) and c)

20

To a solution of 85 gr of 4-(4-dimethylamino)-1-(4'-fluorophenyl)-1-(hydroxybutyl)-3-(hydroxymethyl)-benzonitrile, hydrobromide in 500 ml of water were added 200 ml of ice cooled 2 M NaOH solution and 500 ml of ether. The mixture was stirred for 1/2 hour, the ether phase separated, dried ( $\text{MgSO}_4$ ) and the ether evaporated. The remaining oil was dissolved in 400 ml of 2-propanol at 40°C, and 40 gr of (+)-di-p-tolyltartaric acid (as hydrate) were added under vigorous stirring. After a short while crystallization began. After 3 hours of stirring the precipitated salt was filtered off and dried yielding 29.2 gr (55.1%) of (-)-4-(4-dimethylamino)-1-(4'-fluorophenyl)-1-(hydroxybutyl)-3-(hydroxymethyl)benzonitrile, hemi (+)-di-p-tolyltartaric acid salt. MP: 134-135°C,  $[\alpha]_D = +10.0^\circ$  (c = 1,  $\text{CH}_3\text{OH}$ ). The filtrate is used below.

25

To an ice cooled solution of 14 gr of the (-)-isomer from above as a base in 300 ml of dry toluene were added 16 ml of triethylamine, and 3.6 ml of methansulfonyl chloride in 20 ml of dry toluene were added dropwise during 10 minutes. The reaction mixture was further stirred for 1/2 hour, washed with brine, dried ( $\text{MgSO}_4$ ) and the solvent evaporated. The title compound was purified by column chromatography affording 8 g of (+)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile.  $[\alpha]_D = +12.33^\circ$  (c = 1,  $\text{CH}_3\text{OH}$ ).

35

The oxalic acid salt of the (+)-isomer crystallized from acetone. MP: 147-148°C,  $[\alpha]_D = +12.31^\circ$  (c = 1,  $\text{CH}_3\text{OH}$ ).

40

The pamoic acid salt of the (+)-isomer was prepared in the following manner: To 1.8 g of the base of the (+)-isomer was added 2 g of pamoic acid in 25 ml of MeOH. The mixture was refluxed for an hour and subsequently cooled to room temperature. The precipitate was filtered off yielding 3.0 g of the pamoic acid salt, MP: 264-266°C,  $[\alpha]_D = +13.88^\circ$  (c = 1, dimethylformamide).

45

A 2:1 addition compound of the (+)-isomer with L(+)-tartaric acid was prepared in the following manner: 4 g of the (+)-isomer as base were dissolved in 100 ml of diethyl ether and extracted into 100 ml of water containing 0.8 g of L(+)-tartaric acid by stirring. The organic phase was separated and discarded. The waterphase was freeze-dried in vacuo (< 0.1 mm Hg) for 18 hours leaving 3.8 g of a white powder of the title compound. This addition compound was stable and not hygroscopic.

50

In a corresponding manner as above via the (+)-4-(4-dimethylamino)-1-(4'-fluorophenyl)-1-(hydroxybutyl)-3-(hydroxymethyl)benzonitrile, hemi (-)-di-(p-tolyl)tartaric acid salt ( $[\alpha]_D = -8.9^\circ$  (c = 1,  $\text{CH}_3\text{OH}$ )) which was converted to the corresponding diol base ( $[\alpha]_D = +61.1^\circ$  (c = 1,  $\text{CH}_3\text{OH}$ )) and finally ringclosure reaction yielded 10 gr of (-)-1-(dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile.  $[\alpha]_D = -12.1^\circ$  (c = 1,  $\text{CH}_3\text{OH}$ ).

The oxalic acid salt of the (-)-isomer crystallized from acetone. MP: 147-148°C,  $[\alpha]_D = -12.08^\circ$  (c = 1,  $\text{CH}_3\text{OH}$ ).

55

### EXAMPLE 3

#### Preparation of citalopram by method c)

To an ice cooled solution of 28 gr of racemic diol base, II, in 500 ml of dichloromethane were added 32 ml of triethylamine, and 7.5 ml of methansulfonyl chloride in 30 ml of dichloromethane were added dropwise during 2 hour. The reaction mixture was washed with 0.1 M NaOH solution twice, the organic phase separated, dried ( $MgSO_4$ ) and the solvent evaporated, leaving 21.5 gr of the title ( $\pm$ )-citalopram as a crystalline base. The thus obtained material was dissolved in a mixture of 2-propanol and methanol (2:1) and an equivalent amount of gaseous HBr was introduced. The mixture was left overnight and the precipitated hydrobromide was filtered off. Yield: 26 gr with MP 184-186°C.

The enantiomers from Example 1 were tested for their ability to block 5-HT reuptake in standard and reliable test method. Results are shown in Table I in comparison with the racemic mixture of citalopram.

10

### 5-HTP-POTENTIATION

The test evaluates the ability of the substance to potentiate the effect of 5-HTP, which results in development of 5-HT syndrome (Christensen, Fjalland, Pedersen, Danneskiold-Samsøe and Svendsen; European J. Pharmacol. 41, 153-162, 1977).

#### **Procedure**

20

Each treatment group consists of 3 mice, and two groups are treated with the highest test dose. A control group only treated with 5-HTP is included and a group treated with citalopram 10 mg/kg and a 5-HTP is used as a reference for full 5-HT syndrome

25

#### The route of administration

30 minutes after the administration of the test substance, the other groups are given 5-HTP (100 mg/kg) i.v. (injection time 5-10 sec.). After this 5-HTP dose normal, untreated mice remain unaffected, but if the animals have been pretreated with a substance, which inhibits the uptake of 5-HT or a 5-HT agonist, a 5-HTP syndrome will occur. The symptoms are the same as previously described: 1) excitation, 2) tremor, and 3) abduction of the hind limbs. The animals are observed for 15 minutes and each animal is given one point for each symptom present. Again the result is stated in fractions: 0/9, 1/9, ..., 9/9, where 0, 1, ..., 9 are the number of points per group after the dose in question. The  $ED_{50}$  value is calculated by log-probit analysis.

### **INHIBITION OF $^3$ H-SEROTONIN UPTAKE IN RAT BRAIN SYNAPTOSONES**

40 By this method the inhibition by drugs of the uptake of  $^3$ H-serotonin ( $^3$ H-5-HT) (10 nM) in rat brain synaptosomes is determined in vitro. Method and results in Hyttel, Psychopharmacology 1978, 60, 13-18; Hyttel, Prog.Neuro-Psychopharmacol. & Biol.Psychiat. 1982, 6, 277-295; Hyttel & Larsen, Acta pharmacol. tox. 1985, 56, suppl. 1, 146-153.

45

#### **Procedure**

Male Wistar (Mol:Wist) rats (125-250 g) are sacrificed by decapitation and exsanguinated. Brain tissue (minus cerebellum) is gently homogenized (glass teflon homogenizer) in 40 vol (w/v) of icecold 0.32 M of sucrose containing 1 mM of nalamide. The P<sub>2</sub> fraction (synaptosomal fraction) is obtained by centrifugation (600 g, 10 min and 25000 g, 55 min, 4°C) and suspended in 800 volumes of a modified Krebs-Ringer-phosphate buffer, pH 7.4.

To 4000  $\mu$ l of the synaptosomal suspension (5 mg original tissue) on ice are added 100  $\mu$ l test substance in water. After preincubation at 37° for 5 min, 100  $\mu$ l of  $^3$ H-5-HT (final concentration 10 nM) are added and the samples are incubated for 10 min at 37°C. The incubation is terminated by filtering the samples under vacuum through Whatman GF/F filters with a wash of 5 ml buffer containing 10  $\mu$ M of unlabelled 5-HT. The filters are placed in counting vials and 4 ml of appropriate scintillation fluid (e.g. PicoFluor TM15) are added. After shaking for 1 h and storage 2 h in the dark the content of radioactivity is

determined by liquid scintillation counting. Uptake is obtained by subtracting the nonspecific binding and passive transport measured in the presence of 10  $\mu$ M citalopram (Lu 10-171-B).

For determination of the inhibition of uptake five concentrations of drugs covering 3 decades are used.

The measured cpm are plotted against drug concentration on semilogarithmic paper, and the best fitting s-shaped curve is drawn. The  $IC_{50}$ -value is determined as the concentration, at which the uptake is 50% of the total uptake in control samples minus the nonspecific binding and uptake in the presence of 10  $\mu$ M of citalopram.

Table 1

10

PHARMACOLOGICAL TEST RESULTS		
Compound	5-HTP pot. $ED_{50}$ $\mu$ mol/kg	5-HT uptake inhibition $IC_{50}$ (nM)
(+)-citalopram	2.0	1.1
(-)-citalopram	120	150
( $\pm$ )-citalopram	3.3	1.8

20

(+)1-(3-Dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile ((+)-citalopram) and the non-toxic acid addition salts thereof may be administered to animals such as dogs, cats, horses, sheeps or the like, including human beings, both orally and parenterally, and may be used for example in the form of tablets, capsules, powders, syrups or in the form of the usual sterile solutions for injection. - Results upon administration to human beings have been very gratifying.

Most conveniently the compounds of Formula I are administered orally in unit dosage form such as tablets or capsules, each dosage unit containing the free amine or a non-toxic acid addition salt of one of the said components in an amount of from about 0.10 to about 100 mg, most preferably, however, from about 5 to 50 mg, calculated as the free amine, the total daily dosage usually ranging from about 1.0 to about 500 mg. The exact individual dosages as well as daily dosages in a particular case will, of course, be determined according to established medical principles under the direction of a physician.

When preparing tablets, the active ingredient is for the most part mixed with ordinary tablet adjuvants such as corn starch, potato starch, talcum, magnesium stearate, gelatine, lactose, gums, or the like.

Typical examples of formulas for composition containing (+)-citalopram in the form of an acid addition salt as the active ingredient, are as follows:

40

1) Tablets containing 5 milligrams of (+)-citalopram calculated as the free base:	
Compound 20	5 mg
Lactose	18 mg
Potato starch	27 mg
Saccharose	58 mg
Sorbitol	3 mg
Talcum	5 mg
Gelatine	2 mg
Povidone	1 mg
Magnesium stearate	0.5 mg

50

55

2) Tablets containing 50 milligrams of (+)-citalopram calculated as the free base:

5	(+)-citalopram	50 mg
	Lactose	16 mg
10	Potato starch	45 mg
	Saccharose	106 mg
	Sorbitol	6 mg
	Talcum	9 mg
	Gelatine	4 mg
	Povidone	3 mg
	Magnesium stearate	0.6 mg

15

3) Syrup containing per milliliter:

20	(+)-citalopram	10 mg
	Sorbitol	500 mg
25	Tragacanth	7 mg
	Glycerol	50 mg
	Methyl-paraben	1 mg
	Propyl-paraben	0.1 mg
	Ethanol	0.005 ml
	Water	ad 1 ml

30

4) Solution for injection containing per milliliter:

35	(+)-citalopram	50 mg
	Acetic acid	17.9 mg
	Sterile water	ad 1 ml

40

5) Solution for injection containing per milliliter:

45	(+)-citalopram	10 mg
	Sorbitol	42.9 mg
	Acetic acid	0.63 mg
	Sodium hydroxide	22 mg
	Sterile water	ad 1 ml

Any other pharmaceutical tableting adjuvants may be used provided that they are compatible with the active ingredient, and additional compositions and dosage forms may be similar to those presently used for 50 neuroleptics, analgesics or antidepressants.

Also combinations of (+)-citalopram as well as its non-toxic acid salts with other active ingredients, especially other neuroleptics, thymoleptics, tranquilizers, analgetics or the like, fall within the scope of the present invention.

As previously stated, when isolating the enantiomers of citalopram in the form of an acid addition salt 55 the acid is preferably selected so as to contain an anion which is a non-toxic and pharmacologically acceptable, at least in usual therapeutic doses. Representative salts which are included in this preferred group are the hydrochlorides, hydrobromides, sulphates, acetates, phosphates, nitrates, methanesulphonates, ethane-sulphonates, lactates, citrates, tartrates or bitartrates, pamoates and maleates of the

amines of Formula I. Other acids are likewise suitable and may be employed if desired. For example: fumaric, benzoic, ascorbic, succinic, salicyclic, bismethylenesalicylic, propionic, gluconic, malic, malonic, mandelic, cannamic, citraconic, stearic, palmitic, itaconic, glycolic, benzenesulphonic, and sulphamic acids may also be employed as acid addition saltforming acids.

5 When it is desired to isolate a compound of the invention in the form of the free base, this may be done according to conventional procedure as by dissolving the isolated or unisolated salt in water, treating with a suitable alkaline material, extracting the liberated free base with a suitable organic solvent drying the extract and evaporating to dryness or fractionally distilling to effect isolation of the free basic amine.

10 The invention also comprises a method for the alleviation, palliation, mitigation or inhibition of the manifestations of certain physiological-psychological abnormalities of animals, especially depressions by administering to a living animal body, including human beings, an adequate quantity of (+)-citalopram or a non-toxic acid addition salt thereof. An adequate quantity would be from about 0.001 mg to about 10 mg per kg of body weight in each unit dosage, and from about 0.003 milligrams to about 7 milligrams/kg of body weight per day.

15 It is to be understood that the invention is not limited to the exact details of operation or exact compound or compositions shown and described, as obvious modifications and equivalents will be apparent to one skilled in the art.

20 **Claims**

-1- (+)-1-(3-Dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile and non-toxic acid addition salts thereof.

-2- The pamoic acid salt of (+)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile.


-3- A pharmaceutical composition in unit dosage form comprising as an active ingredient, a compound as defined in claim 1.

-4- A pharmaceutical composition in unit dosage form comprising, as an active ingredient, the compound of claim 2.

30 -5- A pharmaceutical composition in unit dosage form, according to claim 3 or 4, wherein the active ingredient is present in an amount from 0.1 to 100 milligram per unit dose.

-6- A method for the preparation of a compound as defined in claim 1, which comprises, converting (+)-4-(4-dimethylamino)-1-(4'-fluorophenyl)-1-(hydroxybutyl)-3-(hydroxymethyl)-benzonitrile or a monoester thereof in a stereoselective way to (+)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile which is isolated as such or as a non-toxic acid addition salt thereof.

-7-



50 wherein R is hydrogen or F, a labile ester group.

-8- A method for the preparation of 1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile in the form of a racemic mixture which comprises treating 4-(4-dimethylamino)-1-(4-fluorophenyl)-1-(hydroxybutyl)-3-(hydroxymethyl) benzonitrile, esterified at the primary alcohol group with an acid, forming a labile ester, with an agent causing ringclosure and isolating the compound formed as the free base or a pharmaceutically acceptable acid addition salt thereof.



DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
A	CHEMICAL ABSTRACTS, vol. 104, no. 19, 12th May 1986, page 43, abstract no. 161810v, Columbus, Ohio, US; M. HIBERT et al.: "Stereoselective blockade at the 5-HT autoreceptor and inhibition of radioligand binding to central 5-HT recognition sites by the optical isomers of methiothepin", & NEUROPHARMACOLOGY 1986, 25(1), 1-4 ----	1-8	C 07 D 307/87 A 61 K 31/34 // C 07 B 57/00 C 07 C 121/80 C 07 C 143/68
D, A	EP-A-0 171 943 (H. LUNDBECK) * Whole document *----	1-8	
D, A	US-A-4 136 193 (K. P. BOGESO) * Whole document *-----	1-8	
TECHNICAL FIELDS SEARCHED (Int. Cl.4)			
C 07 D 307/00 C 07 C 121/00 C 07 C 143/00			
The present search report has been drawn up for all claims			
Place of search	Date of completion of the search	Examiner	
THE HAGUE	30-08-1989	ALLARD M. S.	
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ..... & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			